Evidence map›Paper›PMID 37375736›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Innate Vascular Failure by Application of Neuroleptics, Amphetamine, and Domperidone Rapidly Induced Severe Occlusion/Occlusion-like Syndromes in Rats and Stable Gastric Pentadecapeptide BPC 157 as Therapy.

Sanja Strbe, Ivan Maria Smoday, Ivan Krezic, Luka Kalogjera, Vlasta Vukovic, Helena Zizek, Slaven Gojkovic, Hrvoje Vranes, Ivan Barisic, Suncana Sikiric and 11 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Sanja StrbeDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Ivan Maria SmodayDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Ivan KrezicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Luka KalogjeraDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0002-1703-0033
Vlasta VukovicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0009-0004-3095-6289
Helena ZizekDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Slaven GojkovicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0003-4020-326X
Hrvoje VranesDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0003-3544-8385
Ivan BarisicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Suncana SikiricDepartment of Pathology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Marijan TepesDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Katarina OrozDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Filip BrkicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0002-4766-386X
Martin DrinkovicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Lidija Beketic OreskovicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Jelena PopicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0002-7757-9984
Alenka Boban BlagaicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Anita SkrticDepartment of Pathology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.ORCID 0000-0002-9275-7283
Mario StaresinicDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Sven SeiwerthDepartment of Pathology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
Predrag SikiricDepartment of Pharmacology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia.
University of Zagreb · HR

Funding

University of Zagreb 099
6 · The paper itself

Abstract

Even before behavioral disturbances, neuroleptics, amphetamine, and domperidone application rapidly emerged severe occlusion/occlusion-like syndrome, shared innate vascular and multiorgan failure in rats, comparable to occlusion/occlusion-like syndrome described with vessel(s) occlusion or similar noxious procedures application. As therapy, i.e., activation of the collateral pathways, "bypassing key" (activated azygos vein pathway, direct blood flow delivery), the stable gastric pentadecapeptide BPC 157 is a novel solution. Recently, BPC 157 therapy particularly counteracted neuroleptic- or L-NAME-induced catalepsy, lithium intoxication, and schizophrenia positive and negative symptoms (amphetamine/methamphetamine/apomorphine/ketamine). In rats with complete calvariectomy, medication (BPC 157 10 µg/kg, 10 ng/kg ip or ig) was given 5 min after distinctive dopamine agents (mg/kg ip) (haloperidol (5), fluphenazine (5), clozapine (10), risperidone (5), olanzapine (10), quetiapine (10), or aripiprazole (10), domperidone (25), amphetamine (10), and combined amphetamine and haloperidol) and assessed at 15 min thereafter. All neuroleptic-, domperidone-, and amphetamine-induced comparable vascular and multiorgan failure severe syndrome was alleviated with BPC 157 therapy as before major vessel(s) occlusion or other similar noxious procedures. Specifically, all severe lesions in the brain (i.e., immediate swelling, hemorrhage), heart (i.e., congestion, arrhythmias), and lung (i.e., congestion, hemorrhage), as well as congestion in the liver, kidney, and gastrointestinal (stomach) tract, were resolved. Intracranial (superior sagittal sinus), portal, and caval hypertension and aortal hypotension were attenuated or eliminated. BPC 157 therapy almost annihilated arterial and venous thrombosis, peripherally and centrally. Thus, rapidly acting Virchow triad circumstances that occur as dopamine central/peripheral antagonists and agonist essential class-points, fully reversed by BPC 157 therapy, might be overwhelming for both neuroleptics and amphetamine.

Indexed as

amphetaminedomperidoneneurolepticsocclusion/occlusion-like syndromespentadecapeptide BPC 157ratsvascular failure

Identifiers

PMID37375736
PMCPMC10303627
OpenAlexW4378223535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.